Immunoprotein Diagnostic Testing Market revenue to hit USD 234 Billion by 2036, says Research Nester
December 06, 2023 05:30 ET
|
Research Nester
New York, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global immunoprotein diagnostic testing market size is predicted to grow at a CAGR of over ~7% from 2024 to 2036. The market is projected to garner a...
Polymerase chain reaction Market Size Worth USD 19.24 Billion in 2032 | Emergen Research
November 21, 2023 10:00 ET
|
Emergen Research
Vancouver, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The global polymerase chain reaction (PCR) market size was USD 8.50 Billion in 2022 and is expected to register a revenue CAGR of 8.5% during the...
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:30 ET
|
OpGen, Inc.
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives,...
Gene Vectors Market Predicted to Rise at a 12.6% CAGR until 2031, Reaching US$ 3.4 billion: TMR Report
October 30, 2023 04:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - TMR predicted that the gene vector market is likely to reach US$ 3.4 billion by 2031. Gene...
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
October 05, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
September 21, 2023 07:55 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
September 20, 2023 09:00 ET
|
GeoVax, Inc.
Preclinical Data for GEO-CM02 Demonstrates Single-Dose ProtectionAgainst Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:...
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
September 19, 2023 09:00 ET
|
GeoVax, Inc.
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
Typhoid Antibody Testing Market Size, Outlook: Exploring the 6.55% CAGR and USD 12.36 Billion Projection by 2030
September 18, 2023 13:32 ET
|
Zion Market Research
New York, NY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Typhoid Antibody Testing Market By End-User (Hospitals, Serological Testing Centers,...
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
September 18, 2023 06:45 ET
|
BioNTech SE
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the...